AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 239 filers reported holding AMICUS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $514,696 | +8.4% | 42,327 | +11.9% | 0.00% | 0.0% |
| Q2 2023 | $475,007 | +22.8% | 37,819 | +8.4% | 0.00% | 0.0% |
| Q1 2023 | $386,963 | -9.2% | 34,893 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $426,349 | +36.2% | 34,918 | +16.4% | 0.00% | 0.0% |
| Q3 2022 | $313,000 | -2.8% | 29,986 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $322,000 | +13.4% | 29,986 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $284,000 | -11.8% | 29,986 | +7.7% | 0.00% | -50.0% |
| Q4 2021 | $322,000 | +20.1% | 27,846 | -0.9% | 0.00% | +100.0% |
| Q3 2021 | $268,000 | -1.1% | 28,094 | +0.0% | 0.00% | -50.0% |
| Q2 2021 | $271,000 | -14.5% | 28,085 | -12.5% | 0.00% | 0.0% |
| Q1 2021 | $317,000 | -53.7% | 32,092 | +8.3% | 0.00% | -50.0% |
| Q4 2020 | $684,000 | +54.4% | 29,633 | -5.6% | 0.00% | +33.3% |
| Q3 2020 | $443,000 | -6.3% | 31,387 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $473,000 | +114.0% | 31,387 | +31.0% | 0.00% | +100.0% |
| Q1 2020 | $221,000 | +22.1% | 23,951 | +28.9% | 0.00% | +100.0% |
| Q4 2019 | $181,000 | +50.8% | 18,577 | +24.7% | 0.00% | 0.0% |
| Q3 2019 | $120,000 | -40.6% | 14,901 | -7.8% | 0.00% | -50.0% |
| Q2 2019 | $202,000 | +40.3% | 16,161 | +53.0% | 0.00% | +100.0% |
| Q1 2019 | $144,000 | +26.3% | 10,566 | -11.4% | 0.00% | 0.0% |
| Q4 2018 | $114,000 | -20.8% | 11,925 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $144,000 | -22.6% | 11,925 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $186,000 | +3.9% | 11,925 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $179,000 | +27.9% | 11,925 | +22.7% | 0.00% | +100.0% |
| Q4 2017 | $140,000 | +29.6% | 9,716 | +36.1% | 0.00% | 0.0% |
| Q3 2017 | $108,000 | +50.0% | 7,138 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $72,000 | +41.2% | 7,138 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $51,000 | +45.7% | 7,138 | 0.0% | 0.00% | – |
| Q4 2016 | $35,000 | +52.2% | 7,138 | +125.2% | 0.00% | – |
| Q3 2016 | $23,000 | +76.9% | 3,170 | +37.3% | 0.00% | – |
| Q2 2016 | $13,000 | -35.0% | 2,308 | 0.0% | 0.00% | – |
| Q1 2016 | $20,000 | -9.1% | 2,308 | 0.0% | 0.00% | – |
| Q4 2015 | $22,000 | +46.7% | 2,308 | +109.8% | 0.00% | – |
| Q3 2015 | $15,000 | +114.3% | 1,100 | +125.9% | 0.00% | – |
| Q2 2015 | $7,000 | – | 487 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |